(Q41966077)

14 October 2017

L-DOPA reversal of hyperdopaminergic behaviour (English)

1 reference

14 October 2017

C. Ezrin-Waters

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A565450

15 July 2023

P. Seeman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A565450

15 July 2023

language of work or name

English

0 references

publication date

1 March 1978

1 reference

full work available at URL

14 October 2017

https://api.elsevier.com/content/article/PII:0024320578902710?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

https://api.elsevier.com/content/article/PII:0024320578902710?httpAccept=text/plain

15 July 2023

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

15 July 2023

1 reference

14 October 2017

22

1 reference

14 October 2017

12

1 reference

14 October 2017

1027-1032

1 reference

NEUROLOGICAL SYMPTOMS IN PHARMACOTHERAPY OF PSYCHOSES

14 October 2017

1

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

15 July 2023

Persistent Dyskinesia

4

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

15 July 2023

Tardive dyskinesia

5

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Effects of prolonged phenothiazine intake on psychotic and other hospitalized children.

15 July 2023

6

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Haloperidol-induced tardive dyskinesia in monkeys

15 July 2023

7

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Hysteria and depression: the frequency and significance of hysterical personality features in hospitalized depressed women.

15 July 2023

8

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Tardive dyskinesia: are first signs reversible?

15 July 2023

9

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Neuropathological findings in three cases of persistent dyskinesia following phenothiazine medication

15 July 2023

10

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Therapeutic approaches to tardive dyskinesia. A review of the literature

15 July 2023

11

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Drug Therapy of Tardive Dyskinesia

15 July 2023

13

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Treatment of drug-induced dyskinesias

15 July 2023

15

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Treatment of tardive dyskinesia. 3. Clinical efficacy of a dopamine competing agent, methyldopa

15 July 2023

16

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate.

15 July 2023

18

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Observations on the effect of levodopa on tardive lingual-facial-buccal dyskinesia

15 July 2023

20

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia

15 July 2023

22

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Methylphenidate in Tardive Dyskinesia

15 July 2023

25

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Deanol in the treatment of levodopa-induced dyskinesias

15 July 2023

26

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Cholinergic suppression of tardive dyskinesia

15 July 2023

27

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Effect of cholinergic and anticholinergic agents on tardive dyskinesia

15 July 2023

28

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Deanol in tardive dyskinesia: a preliminary report

15 July 2023

29

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Deanol in tardive dyskinesia: a double-blind study (author's transl)

15 July 2023

30

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Choline in tardive dyskinesia and Huntington's disease

15 July 2023

31

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

A pharmacologic analysis of Huntington's chorea

15 July 2023

32

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Theoretical implications of the use of L-dopa in parkinsonism. A review

15 July 2023

33

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

The pharmacology of tardive dyskinesias

15 July 2023

34

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Tolerance of haloperidol catalepsy

15 July 2023

36

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines.

15 July 2023

37

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Behavioral evidence for dopaminergic supersensitivity after chronic haloperidol

15 July 2023

38

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Journal of Pharmacology and Experimental Therapeutics

15 July 2023

40

193

88

Vonvoigtlander

1975

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine

15 July 2023

41

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

The effect of long-term penfluridol treatment on the sensitivity of the dopamine receptors in the nucleus accumbens and in the corpus striatum

15 July 2023

42

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine, and thioridazine

15 July 2023

43

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain

15 July 2023

46

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Enhancement of reserpine-elicited dopaminergic supersensitivity by repeated treatment with apomorphine and α-methyl-p-tyrosine

15 July 2023

49

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Rating the behavioral effects of amphetamine

15 July 2023

50

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Inhibition and potentiation of apomorphine-induced hypermotility in rats by neuroleptics

15 July 2023

51

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Blockade of α-methyltyrosine-induced supersensitivity to apomorphine by chronic administration of L-DOPA

15 July 2023

52

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Implications of Amphetamine-Induced Stereotyped Behavior as a Model for Tardive Dyskinesias

15 July 2023

53

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

Long-term changes in the sensitivity of pre-and postsynaptic dopamine receptors in mouse striatum evidenced by behavioural and biochemical studies

15 July 2023

57

1 reference

https://api.crossref.org/works/10.1016/0024-3205(78)90271-0

15 July 2023

Identifiers

1 reference

14 October 2017

1 reference